Xcout Intel
Adocia competitors & alternatives
The 12 closest competitors and alternatives to Adocia among biotechnology companies — ranked by similarity to what Adocia actually does, not by market-cap band.
Subscribe to see Adocia’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Adocia
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Adocia at a glance
Adocia is a biotechnology company headquartered in Victor, France. Xcout tracks 16 named people at Adocia, including Kevin Chen (Chairman of the Board & Chief Executive Officer).
Adocia leadership
- Kevin ChenChairman of the Board & Chief Executive Officer
- Bob Yunjun AiChief Financial Officer & Director
- Olivier SoulaChief Executive Officer Co-founder
- Stéphane BoisselChairman of the Board
- Bob Yunjun AiDirector
- Gang LiDirector
10 more named people on record for Adocia, with roles, board committees and tenure — see the full roster →
Top 12 Adocia competitors
Ranked by semantic similarity — how close each company is to Adocia by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
AdipoPharma is a French biotech company dedicated to understanding the role of adipocyte cells in diabetes, focusing on lipid biosynthesis and whole-body metabolic health.
Similar biotechnology company
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Similar biotechnology company
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
Biotech
Biophytis is a clinical-stage biotechnology company that develops transformational therapies to improve longevity and treat age-related diseases. The company utilizes an AI-driven research platform to discover novel drug candidates, with advanced clinical programs focusing on sarcopenia and obesity.
Biotech
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Similar biotechnology company
Parabolica Therapeutics develops proprietary peptide conjugation technologies focused on obesity and other metabolic conditions. The company researches and advances therapeutic programs through its scientific approach.
Similar biotechnology company
D&D Pharmatech Inc. is a clinical-stage biotechnology company specializing in the development of GLP-1 receptor agonists and proprietary peptide technologies.
Similar biotechnology company
Adipo Therapeutics is a biotechnology company developing treatments for obesity and metabolic-related diseases. The company utilizes Notch-inhibiting nanoparticles to convert energy-storing white fat into energy-burning brown fat to increase energy expenditure and resting metabolic rate.
Similar biotechnology company
Imagine Pharma LLC is a biotechnology company that develops novel polypeptide-based platforms focused on oral delivery for biologic drugs, therapeutics for various disease states, and regenerative medicine. The company aims to create first-in-class treatments for conditions such as diabetes and wound healing, alongside offering oral peptide dietary supplements and functional ingredients for consumers.
Similar biotechnology company
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Biotech
89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.
Similar biotechnology company
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with supplementary operations in Boston, Massachusetts. The company specializes in the development of innovative antibody-drug conjugates (ADCs) targeting various oncology indications. Its pipeline focuses on delivering best-in-class clinical treatments for patients with high unmet medical needs.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Adocia and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Adociaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →